Back to Journals » Clinical Ophthalmology » Volume 14

Four-Year Outcomes of Two Second-Generation Trabecular Micro-Bypass Stents in Patients with Open-Angle Glaucoma on One Medication

Authors Lindstrom R, Sarkisian SR, Lewis R, Hovanesian J, Voskanyan L

Received 19 October 2019

Accepted for publication 17 December 2019

Published 13 January 2020 Volume 2020:14 Pages 71—80

DOI https://doi.org/10.2147/OPTH.S235293

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Scott Fraser


Richard Lindstrom, 1 Steven R Sarkisian, 2 Richard Lewis, 3 John Hovanesian, 4 Lilit Voskanyan 5

1Minnesota Eye Consultants, Minneapolis, MN, USA; 2Oklahoma Eye Surgeons, PLLC, Oklahoma City, OK, USA; 3Sacramento Eye Consultants, Sacramento, CA, USA; 4Harvard Eye Associates, Laguna Hills, CA, USA; 5S.V. Malayan Ophthalmology Centre, Glaucoma Department, Yerevan, Armenia

Correspondence: Richard Lindstrom
Minnesota Eye Consultants, 710 E 24th St, Suite 100, Minneapolis, MN 55404, USA
Tel +1 612-813-3600
Fax +1 952-567-6156
Email rllindstrom@mneye.com

Introduction: This study evaluated long-term reductions in intraocular pressure (IOP) and medication following implantation of 2 second-generation trabecular micro-bypass stents (iStent inject®) in eyes with open-angle glaucoma (OAG) not controlled on 1 preoperative medication.
Material and Methods: In this prospective interventional multi-surgeon study, standalone implantation of 2 iStent inject stents was performed in 57 eyes of 57 subjects with OAG, preoperative IOP of 18– 30 mmHg on 1 medication, and preoperative post-washout IOP of 22– 38 mmHg. The main outcome measures included the proportions of eyes achieving medication-free IOP ≤ 18 mmHg, IOP ≤ 15 mmHg, or ≥ 20% IOP reduction versus preoperative unmedicated IOP. Assessments included IOP, medications, visual acuity, visual field, pachymetry, complications, and interventions. Subjects were followed for 48 months with follow-up continuing in all eyes.
Results: At Month 48 (n=57), 95% of eyes achieved an IOP reduction of ≥ 20% without medication versus preoperative washout IOP; and although they had eliminated medication, 81% of eyes still had an IOP reduction of ≥ 20% versus preoperative IOP on 1 medication. Mean 48-month unmedicated IOP decreased by 46% to 13.2± 1.6 mmHg vs 24.4± 1.3 mmHg preoperatively (p< 0.0001), with 95% of medication-free eyes having IOP ≤ 18mmHg and 82% having IOP ≤ 15mmHg. Over the course of follow-up, 3 eyes had medication added and 1 eye underwent a secondary glaucoma surgery, and safety parameters were favorable.
Discussion: Standalone iStent inject implantation in OAG patients on 1 preoperative medication resulted in average IOP reduction to ≤ 15 mmHg with the elimination of medication and favorable safety through 48 months.
Trial Registration: ClinicalTrials.gov identifier, NCT02868190.

Keywords: glaucoma, MIGS, trabecular micro-bypass, second-generation, prostaglandin, iStent inject

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]